Characterization of Patients with Chronic Myeloid Leukemia Unresponsive to Tyrosine Kinase Inhibitors who Underwent Allogeneic Hematopoietic Stem Cell Transplantation
-
Franceli Carvalho
,
Joice Zuckermann
,
Alessandra Paz
,
Gustavo Fischer
,
Liane Esteves Daudt
,
Lisandra Della Costa Rigoni
,
Lúcia Silla
,
Laura Fogliatto
,
Simone Martins de Castro
,
Diogo André Pilger
Abstract
Background: Tyrosine kinase inhibitors (TKIs) were the first drugs to use an intracellular signaling molecule as a therapeutic target. Unresponsiveness to TKIs limits therapeutic options, making allogeneic hematopoietic stem cell transplantation (HSCT) the only option leading to molecular remission. The aim of this study is to characterize CML patients unresponsive to first- and/or second-generation TKI therapy who underwent HSCT and to describe the main factors associated with treatment failure.
Subjects and Methods: Twenty one CML patients who underwent allogeneic HSCT and had previously used first- and/or second-generation TKIs from January 2005 to May 2014.
Results: Of the 21 patients, 52.4% were male, with a median age of 49 years (23-65 years) and 85.7% had chronic phase CML at the time of diagnosis; 28.6% showed inadequate treatment adherence to TKI therapy. Thirteen patients were resistant and eight were intolerant to TKIs; additionally, nine did not have T315I mutation. Ten transplantations involved related donors, and more than a half of patients (11) died, three of which due to graft failure. Most patients who survived transplantation were in the chronic phase of disease at the time of HSCT.
Conclusion: The population was composed mainly of young age patients at diagnosis, male, white, and coming from areas in the state of Rio Grande do Sul other than Porto Alegre and metropolitan region. Low adherence to TKI therapy may be related to unresponsiveness to treatment, especially in patients with acquired resistance, or this low adherence, together with the presence of molecular changes, may have led to the need for HSCT.
Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. 2014; 89(5):547-56.
Santos FPS, Kantarjian H, Quintas-Cardama A, et al. Evolution of Therapies for Chronic Myelogenous Leukemia. Cancer J. 2011; 17(6):465-76.
An X, Tiwari AK, Sun Y,et al. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review. Leuk Res. 2010; 34(10):1255-68.
Sweet KL, Hazlehurst LA, Pinilla-Ibarz J. The one-two punch: combination treatment in chronic myeloid leukemia. Crit Rev Oncol Hematol. 2013; 88(3):667-79.
Cortes JE, Jones D, O'Brien S, et al. Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase. J Clin Oncol. 2010; 28(3):392-7.
Oyekunle A, Zander AR, Binder M, et al. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Ann Hematol. 2013; 92(4):487-96.
Xu Lp, Huang Xj. Allogeneic hematopoietic stem cell transplantation for the treatment of chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Chinese Med J. 2013; 126(4):768-74.
Champlin R, Jabbour E, Kebriaei P, et al. Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk. 2011; 11(Suppl 1):S96-100.
Trela E, Glowacki S, Błasiak J. Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era? ISRN Oncol. 2014; 2014:596483.
Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010; 28(14):2381-8.
Noens L, Hensen M, Kucmin-Bemelmans I, et al. Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges. Haematologica. 2014; 99(3):437-47.
Yood MU, Oliveria SA, Cziraky M, et al. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr Med Res Opin. 2012; 28(2):213-9.
De Almeida MH, Fogliatto L, Couto D. Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia. Rev Bras Hematol Hemoter. 2014; 36(1):54-9.
Baccarani M, Cortes J, Pane F, et al. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European Leukemia Net. J Clin Oncol. 2009; 27(35):6041-51.
Breccia M, Alimena G. Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs. Mediterr J Hematol Infect Dis. 2014; 6(1): e2014003.
Hughes T, White D. Which TKI? An embarrassment of riches for chronic myeloid leukemia patients. Hematology Am Soc Hematol Educ Program. 2013; 2013:168-75.
Cid DM, Magalhães SM, Quixadá AT, et al. Chronic myeloid leukemia: an overview of the determinants of effectiveness and therapeutic response in the first decade of treatment with imatinib mesylate in a Brazilian hospital. Rev Bras Hematol Hemoter. 2013; 35(6):389-94.
Jain N, Besien VK. Chronic Myelogenous Leukemia: Role of Stem Cell Transplant in the Imatinib Era. Hematol Oncol Clin North Am. 2011; 25(5): 1025–vi.
Veldman R, El Rassi F, Holloway S, et al. Advances in hematopoietic stem cell transplantation in chronic myeloid leukemia. Discov Med. 2013; 16(88):179-86.
Oyekunle A, Zander AR, Binder M, et al. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Ann Hematol. 2013; 92(4):487-96.
| Files | ||
| Issue | Vol 11, No 1 (2017) | |
| Section | Articles | |
| Keywords | ||
| Chronic myeloid leukemia Tyrosine kinase inhibitors Resistance Intolerance | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
